Rufinamide
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Partial Onset Seizures
Conditions
Refractory Partial Onset Seizures
Trial Timeline
Mar 15, 2007 → May 14, 2010
NCT ID
NCT00448539About Rufinamide
Rufinamide is a phase 3 stage product being developed by Eisai for Refractory Partial Onset Seizures. The current trial status is terminated. This product is registered under clinical trial identifier NCT00448539. Target conditions include Refractory Partial Onset Seizures.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Partial Onset Seizures were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03778424 | Pre-clinical | Active |
| NCT02175173 | Pre-clinical | Completed |
| NCT01151540 | Phase 3 | Completed |
| NCT00448539 | Phase 3 | Terminated |
Competing Products
20 competing products in Refractory Partial Onset Seizures